ArticleDiscover oncology2025
Multi-omics analysis of the effects of pla2g4a on the prognosis of various cancers and its experimental validation in breast cancer cell lines.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrative machine learning reveals a TLS signature and CCL5-CCR1 axis-associated immune remodeling in breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Integrative analysis of the meibum microbiome in dry eye disease: from dysbiosis and diagnostic biomarkers to immunomodulation by Bradyrhizobium-derived outer membrane vesicles.Journal of translational medicine · 2026Article
- Decoding the breast cancer microenvironment by spatial multi-omics: from architecture to clinical translation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Integrative Proteomic and Phosphoproteomic Analysis Reveals Altered Vesicle Transport in Systemic Lupus Erythematosus.Clinical proteomics · 2026Article
- Benchmark of biomarker identification and prognostic modeling methods on diverse censored data.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPlatelet-related exosomes (PREs) are microparticles secreted by platelets into the bloodstream and are implicated in various cancer processes. This study aims to identify critical genes involved in Breast Cancer (BC)-associated PREs and to evaluate their role in cancer prognosis. PLA2G4A was identified as a key gene through the use of machine learning techniques and various genomic analyses, providing a foundation for precision medicine in BC treatment.
methodsDownload cancer-related data from databases such as UCSC Xena and ExMdb, use LASSO Cox regression and various machine learning algorithms to screen genes associated with BC survival, and perform functional and pathway enrichment analysis. The expression, immune relevance, diagnostic efficacy, and drug sensitivity of the PLA2G4A gene in pan-cancer and BC were specifically analyzed. The function of PLA2G4A in BC was validated through experiments, and its drug response and molecular docking were predicted using various databases and software tools.
resultsMachine learning methods and LASSO Cox regression were applied to analyze the relationship between gene expression and BC survival. PLA2G4A was identified as a key gene associated with cancer prognosis, supported by analyses of differential gene expression, survival outcomes, single nucleotide variations (SNVs), and copy number variations (CNVs). Biological pathway analyses through KEGG, GO, and GSEA highlighted PLA2G4A's involvement in key cancer-related processes. In vitro studies, including cell scratch assays, Transwell migration assays, and EdU proliferation tests, demonstrated that overexpression of PLA2G4A inhibited the proliferation and migration of BC cells.
conclusionsPLA2G4A plays a crucial role in the progression of BC, acting as a potential tumor-suppressor gene. The findings support its potential as a prognostic biomarker and further investigation is needed to explore its therapeutic potential in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.